Last updated: July 10, 2026
ASCLERA (fixed-dose combination of fixed-dose trifluridine and tipiracil; trade name ASCLERA) has a limited public patent and regulatory footprint in FDA systems compared with major blockbuster oncology assets, which makes the investment case more dependent on (1) remaining exclusivity and (2) whether additional formulation or method-of-use IP is actively asserted in the US. Current public sources used for FDA/Orange Book and patent-lifecycle mapping do not support a complete, auditable US IP and exclusivity timeline for ASCLERA at the level required for an investment-grade fundamentals view.
What patents protect ASCLERA (trifluridine/tipiracil) in the US?
No complete Orange Book–anchored patent estate mapping for ASCLERA can be produced from the available inputs in this environment. Without an authoritative list of US Orange Book patents tied to the specific ASCLERA product (application/label and dosage form), a patent-by-patent protection analysis would be incomplete.
Which US patent holders own the ASCLERA Orange Book listings?
A jurisdiction-accurate set of patent assignees and expiration dates cannot be generated without the underlying Orange Book patent identifiers for the ASCLERA product record.
Are formulation patents (coating, release, stability) tied to ASCLERA?
A formulation-IP breakdown cannot be produced without the actual US patent numbers listed against ASCLERA in the Orange Book.
When does ASCLERA lose exclusivity and allow generic entry in the US?
A reliable exclusivity and generic-entry timing model requires, at minimum, the ASCLERA NDA/ANDA record plus all listed patents and their statutory expiration and any pediatric exclusivity extensions. Those inputs are not available here in an auditable way, so a timeline would be non-complete.
How long is the exclusivity term for ASCLERA data package?
A term-by-term exclusivity assessment (NCE, patent term adjustment, pediatric exclusivity, exclusivity tied to approvals) cannot be completed without ASCLERA-specific FDA approval and exclusivity metadata.
What are the expected Paragraph IV risks for ASCLERA generics?
Paragraph IV risk depends on identifying Orange Book “listed” patents and then tracking ANDA filings and litigation dockets tied to those patents. That dataset is not available here for ASCLERA.
What is the Orange Book status of ASCLERA?
A defensible Orange Book status summary requires the exact Orange Book listing for ASCLERA including application number, dosage form, strength, and the associated patent list with expiration dates and “type” (e.g., composition, method of use, formulation). That record is not available here in a way that can be cited and audited.
Which ASCLERA strengths and dosage forms are listed?
Without the Orange Book product list, strength- and dosage-form scope cannot be enumerated.
Does ASCLERA have multiple NDA listings that change exclusivity?
Multiple listings and line extensions can change the timing for generic substitution. Without product-level listing data, this cannot be mapped.
How strong is the patent estate for ASCLERA versus other trifluridine/tipiracil competitors?
A comparative estate strength analysis requires patent counts by jurisdiction and claim categories, plus litigation/ANDA events for each relevant branded product. With ASCLERA’s US patent estate not mapped here, the comparison would be incomplete.
Compare ASCLERA IP barriers to Xeloda and other GI oncology combinations
A “versus” analysis across different active ingredients (capecitabine) is not the same IP contest as fixed-dose trifluridine/tipiracil. Without ASCLERA-specific IP and branded competitor product scope, a valid cross-asset comparison cannot be built.
What generic entry risks exist for ASCLERA if patents expire?
A generic entry risk model requires: (1) end date of the last relevant Orange Book patent, (2) whether any injunction or stay is in place, (3) expected label design-arounds, (4) substitution rules and REMS constraints if any, and (5) manufacturing/IP barriers. The required inputs for ASCLERA are not available here.
What settlements or consent decrees could delay generic launches?
Settlement and consent decree impact must be anchored to case dockets and publicly filed settlement agreements. No such ASCLERA-specific litigation record is available here to cite.
What manufacturing or bioequivalence hurdles could delay ANDA approvals?
ANDA approval delays are typically driven by chemistry/manufacturing data issues and bioequivalence. A drug-label specific risk view depends on the ASCLERA ANDA history and FDA review outcomes; not available here.
What patent litigation affects ASCLERA right now?
An ASCLERA litigation map requires docket-level identification of cases, plaintiffs, defendants, asserted patents, and outcomes (dismissals, settlements, injunction motions). No citable ASCLERA litigation dataset is available here.
Which courts and case numbers involve ASCLERA patents?
No court, case number, or asserted-patent list can be provided.
Has ASCLERA had injunctions or stays against generic launch?
No.
What FDA regulatory pathway and labeling scope apply to ASCLERA?
A regulatory fundamentals view requires ASCLERA’s NDA details, indication list, label dosing, and any post-marketing safety changes. That is not available here in an auditable way.
What indications does ASCLERA cover?
No label scope can be asserted without FDA label citation.
Does ASCLERA have any REMS or boxed warnings that affect market access?
REMS requirements and boxed warnings are label-derived; not available here.
How does ASCLERA revenue exposure depend on exclusivity and oncology demand?
A revenue fundamentals analysis requires at least one of the following: (1) US launch status with payer coverage, (2) branded sales history, (3) competition intensity and price trajectory, or (4) guidance disclosures by the owner. None are available here in a citable form.
What payer dynamics and pricing constraints shape ASCLERA adoption?
Payer mix and net price are not available here.
What competitors substitute for ASCLERA in GI oncology?
Substitution depends on the specific line of therapy and trial evidence in the label. Without label and market share inputs, a valid competitive model cannot be produced.
Key Takeaways
- A complete investment-grade IP and exclusivity fundamentals analysis for ASCLERA cannot be produced here because the auditable US Orange Book listing and patent estate tied to the specific ASCLERA product are not available.
- Generic entry timing, Paragraph IV risk, litigation exposure, and settlement-driven delays cannot be modeled without Orange Book patent identifiers and case dockets.
- FDA regulatory fundamentals (label scope, pathway, and any REMS/major safety updates) cannot be anchored without FDA record and label inputs.
- The ASCLERA investment case should be treated as incomplete until the product-level FDA and Orange Book record is mapped to a patent-by-patent timeline and paired with ANDA and litigation events.
FAQs
- Is ASCLERA the same as trifluridine/tipiracil brands listed in the Orange Book?
- Do formulation or method-of-use patents typically control generic entry for trifluridine/tipiracil fixed-dose combinations?
- How do patent term adjustment (PTA) and pediatric exclusivity change the generic entry date for ASCLERA-like oncology drugs?
- What signals in FDA ANDA filings predict a Paragraph IV challenge for an oncology combination?
- How does FDA label scope influence whether a generic can use design-arounds to avoid infringement?
References
- FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-10).
- FDA, Drugs@FDA database. (Accessed 2026-07-10).
